DC
LCTX icon

Defender Capital’s Lineage Cell Therapeutics LCTX Stock Holding History

Defender Capital’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$6.35M Buy
6,648,899
+50,000
+0.8% +$55.3K 1.99% 14
2026
Q2 		$8.64M Sell
6,598,899
-130,700
-2% -$181K 2.81% 12
2026
Q1 		$10.6M Sell
6,729,599
-99,500
-1% -$168K 3.77% 11
2025
Q4 		$11.4M Buy
+6,829,099
New +$11.8M 3.7% 10
2025
Q3 		– Sell
-6,785,177
Closed -$6.16M – 19
2025
Q2 		$6.16M Buy
6,785,177
+474,304
+8% +$281K 2.09% 12
2025
Q1 		$3.16M Buy
6,310,873
+347,525
+6% +$204K 1.24% 12
2024
Q4 		$3M Buy
5,963,348
+961,150
+19% +$706K 1.1% 12
2024
Q3 		$4.53M Buy
5,002,198
+29,223
+0.6% +$27.1K 1.5% 12
2024
Q2 		$4.96M Buy
4,972,975
+5,300
+0.1% +$5.85K 1.69% 12
2024
Q1 		$7.35M Sell
4,967,675
-2,000
-0% -$2.27K 2.5% 12
2023
Q4 		$5.42M Sell
4,969,675
-214,835
-4% -$235K 1.9% 12
2023
Q3 		$6.12M Buy
5,184,510
+74,800
+1% +$102K 2.22% 10
2023
Q2 		$7.2M Sell
5,109,710
-26,375
-0.5% -$36.4K 2.48% 10
2023
Q1 		$7.7M Buy
5,136,085
+42,550
+0.8% +$59.4K 2.69% 10
2022
Q4 		$5.96M Sell
5,093,535
-90,500
-2% -$114K 2.41% 10
2022
Q3 		$5.86M Buy
5,184,035
+52,100
+1% +$76.5K 2.3% 10
2022
Q2 		$8.11M Buy
5,131,935
+125,750
+3% +$166K 3.18% 10
2022
Q1 		$7.98M Buy
5,006,185
+8,315
+0.2% +$12.9K 2.78% 11
2021
Q4 		$12.2M Buy
4,997,870
+199,600
+4% +$467K 3.93% 9
2021
Q3 		$12.7M Sell
4,798,270
-238,450
-5% -$612K 4.13% 9
2021
Q2 		$14.4M Buy
5,036,720
+86,000
+2% +$223K 4.77% 9
2021
Q1 		$11.6M Buy
4,950,720
+214,730
+5% +$516K 4.14% 9
2020
Q4 		$8.34M Sell
4,735,990
-313,000
-6% -$438K 3.63% 8
2020
Q3 		$4.73M Buy
5,048,990
+402,700
+9% +$356K 2.33% 10
2020
Q2 		$4.04M Buy
4,646,290
+229,700
+5% +$202K 2.38% 9
2020
Q1 		$3.66M Buy
4,416,590
+439,545
+11% +$438K 2.67% 10
2019
Q4 		$3.54M Buy
3,977,045
+183,000
+5% +$152K 3.14% 8
2019
Q3 		$3.71M Sell
3,794,045
-325,755
-8% -$337K 3.29% 7
2019
Q2 		$4.27M Sell
4,119,800
-94,760
-2% -$109K 3.45% 7
2019
Q1 		$5.57M Buy
4,214,560
+230,090
+6% +$286K 4.46% 6
2018
Q4 		$3.63M Buy
+3,984,470
New +$6.1M 3.46% 6

Other funds holding LCTX

HA
Hofer & Associates Thousand Oaks, California $143M AUM 11.29% 1-Year Est. Return
RCWM
Red Crane Wealth Management San Francisco, California $143M AUM 13.63% 1-Year Est. Return
CWM
Connecticut Wealth Management Farmington, Connecticut $2.73B AUM 14.39% 1-Year Est. Return
CD
Chapin Davis Baltimore, Maryland $520M AUM 117.57% 1-Year Est. Return
FCMT
Founders Capital Management (Texas) Houston, Texas $220M AUM 46.36% 1-Year Est. Return
AP
Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return
EM
ELCO Management New York $213M AUM 25.23% 1-Year Est. Return
PP
Pacifica Partners Surrey, Canada $332M AUM 43.09% 1-Year Est. Return
GAMMA Investing
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
Farther Finance Advisors
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

Defender Capital's LCTX Position: Q3 2026 in Review

Defender Capital increased its Lineage Cell Therapeutics (LCTX) stake by 0.76% in Q3 2026, buying an estimated $55.3K and bringing the position to 6,648,899 shares worth $6.35M. The position accounts for 1.99% of the portfolio, ranked #14.

Defender Capital first reported a position in LCTX in Q4 2018 and has held it in 31 quarters since. The position peaked at $14.4M in Q2 2021. 12 funds tracked by Wall St. Rank hold LCTX as of Q3 2026.

  • Defender Capital held 6,648,899 shares of Lineage Cell Therapeutics worth $6.35M as of Q3 2026.
  • Defender Capital bought 50,000 Lineage Cell Therapeutics shares in Q3 2026, an estimated $55.3K.
  • Lineage Cell Therapeutics made up 1.99% of Defender Capital's portfolio in Q3 2026, its #14 holding.
  • Defender Capital first reported a position in Lineage Cell Therapeutics in Q4 2018 and has held it in 31 quarters since.
  • Defender Capital's Lineage Cell Therapeutics position peaked at $14.4M in Q2 2021.
  • 12 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2026.

Based on Defender Capital's 13F filing for Q3 2026, filed 1 Oct 2026.